Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California. Show more
Location: 1599 Industrial Road, San Carlos, CA, 94070, United States | Website: https://biomeafusion.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
102.6M
52 Wk Range
$1.29 - $13.07
Previous Close
$1.80
Open
$1.80
Volume
2,197,124
Day Range
$1.63 - $1.80
Enterprise Value
39.69M
Cash
35.86M
Avg Qtr Burn
-28.38M
Insider Ownership
9.76%
Institutional Own.
45.04%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Data readout | ||
Phase 2 Initiation | ||
BMF-219 (icovamenib) Details Type 2 diabetes | Phase 1/2 Data readout | |
BMF-500 Details Leukemia | Phase 1 Update | |
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia | Failed Discontinued | |
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Failed Discontinued |